- Home
- LFT vs TCRX Comparison
LFT vs TCRX Comparison
Compare LFT & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | TCRX |
|---|---|---|
| Founded | 2012 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 64.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | LFT | TCRX |
|---|---|---|
| Price | $1.30 | $1.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 262.6K | ★ 622.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | ★ 11.94% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $21,708,246.00 | $8,423,000.00 |
| Revenue This Year | $124.75 | $286.83 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.23 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $0.88 |
| 52 Week High | $2.84 | $3.13 |
Technical Indicators
Market Signals| Indicator | LFT | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.96 | 61.42 |
| Support Level | $1.44 | $0.88 |
| Resistance Level | $1.52 | $1.10 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 2.13 | 94.08 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.